Prognostic significance of c-erbB2 protein in endometrial cancer.
The human protooncogene c-erbB2, also known as HER-2/neu is sited on 17q21 chromosome and codifies a transmembranous glycoprotein of 185 KD, named c-erbB2 protein, with tyrosin-kinasic activity and homologue from molecular point of view with the epidermal growth factor receptor (EGFR). In order to detect the tissular expression of c-erbB2 protein, tissular samples from 10 patients with primary endometrial cancer were immmunohistochemically processed. C-erbB2 immunostaining using c-erbB2 (21N) antiserum marked the cellular membranes and, occasionally, the cytoplasma of the tumoral cells. The overexpression of c-erbB2 protein in the examed cases was correlated with the clinical status, histological type of the tumour and the differentiation degree. All the patients presented immunoreactivity of variable intensity for c-erbB2 protein. The alterations of c-erbB2 protein are considered to be an unfavourable prognostic factor implied in the tumoral progression.
Lazăr
E
E
Department of Morphopathology, University of Medicine and Pharmacy, Timişoara.
Tudose
N
N
Lazăr
D C
DC
D000231:Adenocarcinoma, Papillary / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D000368:Aged; D018196:Carcinoma, Adenosquamous / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D018719:Erb-b2 Receptor Tyrosine Kinases